An application made for this job — a tailored resume and cover letter that speak straight to the posting.
Shennon Bio is seeking a senior R&D leader to head the therapeutics R&D function and drive the company’s immuno-oncology programs from target discovery through clinic. You will partner with the CEO and advisors to shape strategy, scale collaborations, and advance lead candidates to IND and clinical trials.
The role requires a Ph.D. in immuno-oncology with 10+ years of industry experience, proven ability to manage cross-functional teams, and a track record of building pharma partnerships.
We are a well-funded biotech company that is redefining drug discovery and development through our fully integrated platform. We combine ultra-high-throughput microfluidics driven functional screening, computational engineering, and translational immunology into a unified engine. Rather than approaching drug development as a series of disconnected steps, we seamlessly integrate the discovery of novel targets, functional screening of binders, computational optimization, and predictive safety assessment to develop more better and safer therapeutics. This end-to-end approach enables faster iteration, deeper biological insight, and the development of better drugs with greater precision and confidence.
Reporting to the Chief Executive Officer, the CSO is an accomplished scientific leader, who can professionally and effectively execute the research initiatives towards Shennon Bio’s vision and strategy. This role will lead the R&D function on the therapeutics side and play a critical part in developing biopharma partnerships. An ideal candidate will be an R&D leader with a passion for immunotherapy and knows how to bring TCE candidates into the clinic.
This person will maintain professional and productive relationships with internal colleagues and external collaborators with an entrepreneurial & go-to-market mindset. Shennon Bio’s vision of this candidate is an organized leader that has a self-starter attitude and a strong background in immune-oncology and TCE development.
Collaboration, Ownership and Authenticity.